Table 2.

Unadjusted and Weighted Joint Effects of ART Initiation and Depressive Symptoms on All-Cause Mortality in the Women's Interagency HIV Study, United States, 1998–2011

Model and ART/Depressive Symptom Status	Deaths	Women-Years	IRa	HR	95% CI	P for Interactionb
Unadjusted
ART, no depressive symptoms	36	2,341	1.54	1		0.80
ART, depressive symptoms	86	1,686	5.10	3.35	2.26, 4.96
No ART, no depressive symptoms	19	1,506	1.26	0.88	0.50, 1.54
No ART, depressive symptoms	53	1,187	4.46	3.20	2.06, 4.97
Weightedc
ART, no depressive symptoms	34	2,548	1.35	1		0.78
ART, depressive symptoms	86	1,968	4.39	3.60	2.02, 6.43
No ART, no depressive symptoms	33	1,356	2.46	2.36	1.16, 4.81
No ART, depressive symptoms	86	1,136	7.55	7.47	3.91, 14.3
Truncatedd
ART, no depressive symptoms	34	2,517	1.36	1		0.78
ART, depressive symptoms	80	1,877	4.27	3.32	1.99, 5.54
No ART, no depressive symptoms	33	1,348	2.47	2.25	1.14, 4.43
No ART, depressive symptoms	80	1,129	7.06	6.64	3.69, 11.9
Weightede
ART, no depressive symptoms	49	2,813	1.73	1		0.92
ART, depressive symptoms	86	2,037	4.21	3.23	1.61, 6.47
No ART, no depressive symptoms	32	1,366	2.36	1.94	0.91, 4.15
No ART, depressive symptoms	87	1,133	7.64	6.58	3.28, 13.2

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; IR, incidence rate.

^a Incidence rate per 100 women-years.

^bP value for the term for interaction between the 2 joint exposures, ART initiation and depressive symptoms.

^c Weighted models adjusted for age at enrollment, race, CD4 cell count, log₁₀ HIV RNA, baseline CD4 cell count, and baseline log₁₀ HIV RNA. Weights for depressive symptoms also adjusted for depressive symptoms at the previous visit.

^d Weights truncated at 0.1 and 10.

^e Weighted models further adjusted for substance abuse.